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Abstract
Background: Prolactin is a polypeptide hormone responsible for proliferation and differentiation of the mammary
gland. More recently, prolactin’s role in mammary carcinogenesis has been studied with greater interest. Studies
from our laboratory and from others have demonstrated that three specific isoforms of the prolactin receptor
(PRLR) are expressed in both normal and cancerous breast cells and tissues. Until now, reliable isoform specific
antibodies have been lacking. We have prepared and characterized polyclonal antibodies against each of the
human PRLR isoforms that can effectively be used to characterize human breast cancers.
Methods: Rabbits were immunized with synthetic peptides of isoform unique regions and immune sera affinity
purified prior to validation by Western blot and immunohistochemical analyses. Sections of ductal and lobular
carcinomas were stained with each affinity purified isoform specific antibody to determine expression patterns in
breast cancer subclasses.
Results: We show that the rabbit antibodies have high titer and could specifically recognize each isoform of PRLR.
Differences in PRLR isoform expression levels were observed and quantified using histosections from xenografts of
established human breast cancer cells lines, and ductal and lobular carcinoma human biopsy specimens. In
addition, these results were verified by real-time PCR with isoform specific primers. While nearly all tumors
contained LF and SF1b, the majority (76%) of ductal carcinoma biopsies expressed SF1a while the majority of
lobular carcinomas lacked SF1a staining (72%) and 27% had only low levels of expression.
Conclusions: Differences in the receptor isoform expression profiles may be critical to understanding the role of
PRL in mammary tumorigenesis. Since these antibodies are specifically directed against each PRLR isoform, they are
valuable tools for the evaluation of breast cancer PRLR content and have potential clinical importance in treatment
of this disease by providing new reagents to study the protein expression of the human PRLR.
Background
The role of prolactin (PRL) in human breast cancer is
now becoming more clearly defined. Recent epidemiolo-
g i ce v i d e n c ec l e a r l ys h o w st h a ti nb o t hp r e -a n dp o s t -
menopausal women with serum prolactin levels in the
highest quartile have a significant increased risk of
developing breast cancer [1,2]. PRL, acting through is
receptors, has definitively been shown to increase cell
proliferation and decrease apoptosis in breast cancer
cells in culture [3,4]. Additionally, PRL is a pro-angio-
genesis factor both in normal and cancerous mammary
tissue [5,6]. We [7] and others [8] have shown the exis-
tence of several receptor isoforms whose involvement in
PRL-induced cell proliferation and decreased apoptosis
remains to be fully defined.
The PRLR is a member of the class I cytokine/hema-
topoietic receptor superfamily, characterized by a single
hydrophobic transmembrane region that separates the
ligand-binding extracellular from the signaling intracel-
lular domain. There are five cell-associated isoforms of
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short forms (SF1a and SF1b) [4,9] that differ only in
their C-terminal cytoplasmic domains. The expression
of the PRLR is regulated by PRL itself where low levels
of PRL upregulate and high levels of PRL downregulate
the receptor [10]. The three major cell associated iso-
forms of the PRLR, the LF, that signals for all known
functions including growth and differentiation, and two
short forms, SF1a and SF1b, whose functions, other
than their ability to act as dominant negatives for differ-
entiation in transfected cultured cells [7,8,11,12], are
still largely undefined. Studies from our laboratory and
from others [7,12] have demonstrated that mRNA for
the three specific isoforms of the PRLR is expressed in
both normal and cancerous human breast cells and
tissues.
Ductal and lobular carcinomas are the most common
histological types of breast cancer. This nomenclature
and system of classification is not without controversy
since both originate from the same anatomical structure,
the terminal ductal lobular unit. Most pathologists label
tumors by their grade, size, stage, and hormone receptor
(estrogen receptor, ER; progesterone receptor, PR and
Her2) status. Lobular carcinomas represent approxi-
mately 10% of breast cancers and are biologically dis-
tinct from ductal carcinomas [13] that have defined
tumor foci. Lobular carcinomas appear spindly, tend to
grow in sheets and, therefore, do not present as a mass.
As a result, lobular carcinomas are more difficult to
diagnose clinically and tend to be treated more aggres-
sively [13]. But in spite of this, lobular carcinomas can
be treated successfully by surgical or chemotherapeutic
intervention. While there appears to be no survival
advantage between the two types of cancers, develop-
ment and progression of the disease varies [14,15].
On a molecular level, there are many differences
between ductal and lobular carcinomas. Using microar-
ray techniques and three types of statistical analyses,
Zhao et al. [16] demonstrated that genes differentially
expressed between ductal and lobular carcinomas code
for proteins involved in cell motility/adhesion, fatty acid
transport and metabolism, immune response, and elec-
tron transport. Most genes that significantly distinguish
lobular carcinoma were involved in cell growth and
immune response, but their function remains unknown.
Previous work using B6.2, a PRLR monoclonal anti-
body characterized in our laboratory [17] that is unable
to distinguish the various isoforms, indicated a lack of
correlation between PRLR expression and tumor grade,
size or axillary lymph node status [18]. However, dis-
tinct differences were observed for the site of PRLR
expression among normal, benign, and malignant breast
tissue. Previous studies had suggested that in some sub-
groups of breast cancer patients, detection of PRLR may
have prognostic significance [19]. With the discovery of
the various isoforms of the PRLR, a more detailed analy-
sis of the cellular localization of the receptor as well as
possible differences between subtypes of breast cancer
was warranted. To facilitate these studies we developed
and characterized PRLR isoform specific polyclonal anti-
bodies that reveal that three isoforms, LF, SF1a and
SF1b, are differentially expressed in ductal and lobular
carcinoma tissues.
Methods
Preparation of the polyclonal isoform specific antibodies
Synthetic peptides were designed based on the regions
of unique intracellular sequences of the PRLR splice var-
iants (Table 1), synthesized (AnaSpec, Inc. San Jose, CA)
by the solid-phase method and conjugated to Keyhole
limpet hemocyanin [20]. New Zealand white female rab-
bits (3-5 kg) were immunized (Animal Pharm Services,
Healdsburg, CA) with the conjugated peptides as pre-
viously described [20]. Crude antisera was covalently
linked to Affi-Gel 15 (Bio-Rad, Richmond, CA) and affi-
nity purified by anion-exchange chromatography as
described [21].
Cell culture and transfection
Chinese hamster ovary cells (CHO-K1, ATCC, Mana-
ssas, VA) were maintained in a-MEM (Invitrogen,
Gaithersburg, MD) supplemented with 5% fetal bovine
serum (FBS, Invitrogen) and penicillin/streptomycin
(100 U/ml and 100 ug/ml respectively, Invitrogen).
Transfections were performed using FuGENE 6 (Roche
Applied Science, Indianapolis, IN) at a ratio of 1 μg
DNA to 3 μl FuGENE. The PRLR isoform specific
cDNA constructs were previously described [7]. Cells
were transfected for 48 hr, then allowed to grow for an
additional 48 hr.
T47D and MDA-MB-231 cells (purchased from
ATCC, Rockville, MD) were grown in RPMI1640
Table 1 Peptide sequence
LF 259 KGFDAHLLEKGKSEELLSALGCQDFPPTSDYEDLLVEYLEVD
SF1a 259 KGFDAHLLEKGKSEELLSALGCQDFPPTSDYEDLLVEYLEVD
SF1b 259 KGYSMVTCIFPPVPGPKIKGFDAHLLEVTP
LF 319 DSEDQHLMSVHSKEHPSQGMKPTYLDPDTDSGRGSCDSPSL
SF1a 319 DSEDQHLMSVHSKEHPSQGDPLMLGASHYKNLKSYRPRKIS
LF 360 LSEKCEEPQANPSTFYDPEVIEKPENPETTHTWDPQCIS
SF1a 360 SQGRLAVFTKATLTTVQ
LF 400 MEGKIPYFHAGGSKCSTWPLPQPSQHNPRSSYHNITDVCELAVGPA
445 GAPATLLNEAGKDALKSSQTIKSREEGKATQQREVESFHSETDQD
490 TPWLLPQEKTPFGSAKPLDYVEIHKVNKDGALSLLPKQRENSGK
535 PKKPGTPENNKEYAKVSGVMDNNILVLVPDPHAKNVACFEESAKEA
580 PPSLEONOAEKALANFTATSSKCRLOLGGLDYLDPACFTHSFH
bold indicates unique synthesized sequences
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Page 2 of 11supplemented with 5% FBS, penicillin (100 U/ml), strep-
tomycin (100 μg/ml) and 10 μg/ml insulin. MCF7 cells
(ATCC) were routinely grown in DMEM supplemented
with 5% FBS, penicillin/streptomycin, and insulin. All
cells were maintained at 37° in a humidified chamber
under 5% CO2 in air.
Western blot analysis
Transfected CHO cells were collected and whole cell
lysates were prepared in Complete Buffer (Roche
Applied Science) according to the manufacturer’s
instructions. Total protein was estimated according to
Bradford [22]. Protein (100 μg) was subjected to 10-20%
SDS-PAGE (Invitrogen). Proteins were transferred to
nitrocellulose membrane and probed with isoform speci-
fic antibodies. Commercially prepared antibodies to the
extracellular domain or SF1a of the PRLR (Invitrogen)
were tested in parallel. Lysates from MDA MB 231 or
MCF7 xenografts were similarly analyzed.
For immunoprecipitation studies, 500 μgo fp r o t e i n
from whole cell lysates was bound to 10 μg/ml of iso-
f o r ms p e c i f i ca n t i b o d y[ 7 ] . Equal amounts of protein
(100 μg) were separated by 10-20% SDS-PAGE and
probed with its respective antibody. Reactivity was
detected using ECL Plus (GE Healthcare Life Science,
P i t t s b u r g h ,P A ) .M o l e c u l a rs ize determinations were
made using BenchMark Protein Ladder (Invitrogen).
Tumor xenografts in mice
Female athymic nude mice (4-6 wks of age) were pur-
chased from the NCI colony (APA, Frederick, MD). All
animals were maintained on a 12 hr light/12 hr dark
schedule with free access to laboratory chow and water.
All animal experiments were conducted in accord with
accepted standards of humane animal care and approved
by the Animal Care and Use Committee at the National
Institutes of Health. Breast cancer cells (2 × 10
6 cells)
were injected into the cleared mammary fat pads [23]
and monitored for tumor formation. Once tumors
reached 1 cm
2 (measured in two dimensions, length ×
width), they were excised and fixed in 10% normal
buffered formalin (Fisher, Pittsburgh, PA). Four micron
thick sections were cut and stained with hematoxylin/
eosin for histological examination or used for
immunohistochemistry.
Immunohistochemistry
Immunostaining for specific PRLR isoforms (10 μg/ml)
was carried out using the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA) according to the manu-
facturer’s instruction. Color was developed with diami-
nobenzidine peroxidase (DAB) substrate kit (Vector)
and counterstained with hematoxylin.
Fluorescent immunocytochemistry
CHO cells were plated on 8-well glass chamber slides
(Nunc, Rochester, NY) and transfected as above. After
blocking in 5% normal goat serum (Jackson Labora-
tories, Bar Harbor, ME) prepared in PBS-0.1% Triton,
slides were incubated with the PRLR isoform specific
antibodies (10 μg/ml) for 2 hr at room temperature. In
all cases no primary antibody served as the negative
control. Slides were washed four times with PBS-0.1%
Triton followed by incubation for 1 hr with red fluores-
cent tagged goat anti-rabbit secondary antibody (Alexa-
Fluor 594, 1:500, Invitrogen) in the dark. After extensive
washing with PBS containing Triton, slides were
mounted with Prolong Gold antifade reagent with DAPI
(Invitrogen). The fluorescent staining pattern of the
receptor isoforms was evaluated using an Olympus
BX40 fluorescence microscope (Olympus America, Cen-
ter Valley, PA).
For fluorescent immunohistochemistry breast tumor
samples were supplied by either the Cooperative Human
Tissue Network, a NCI supported resource that supplies
human biospecimens to IRB approved researchers or as
high density breast arrays purchased from US Biomax,
Inc (Rockville, MD). The tissues obtained for analysis
were considered pathological medical waste; thus any
clinical details of the women were unattainable. In addi-
tion, the specimens were fixed in formalin to most clo-
sely replicate tissue processing in the clinic. PRLR
isoform expression was examined on 12 lobular carci-
noma and 10 ductal carcinoma specimens obtained
from CHTN; other investigators may have received sam-
ples from these same tissues. Samples were fixed in 10%
normal buffered formalin, embedded, cut into four
micron sections, and deparaffinized prior to staining.
Two separate tissue arrays, one containing 188 indivi-
dual cases consisting of multiple types of infiltrating
ductal (144), lobular carcinoma (24), and normal breast
and the other containing 80 individual lobular carcino-
mas were utilized; 10 cores from the latter array were
used as negative controls (no primary antibody). Slides
were deparaffinized and antigen retrieval was performed
according to the manufacturer’s recommendations. Sec-
tions were permeabilized in PBS-0.1% Triton for 5 min
and stained as above.
Measurement of fluorescence intensity
Because serial sections for the tumor samples and on
the tissue arrays were used, the same region of each tis-
sue could be measured for fluorescence intensity using
Adobe Photoshop (Adobe Systems Inc., Beaverton, OR).
Nearly every cell in positive samples showed some level
of PRLR isoform expression; as a result, red fluorescence
intensity was used to compare levels of isoform
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Page 3 of 11expression between samples. In order to do this, the
same fluorescent areas were selected from each serial
section using the lasso and rectangular marquee tools.
Selected sections were analyzed using the histogram
function through the red channel, which gave the mean
red intensity of the selected section. Photoshop assigns
intensity values between 0 and 255 to each pixel in the
selected area and then averages these intensities. The
distribution of these means was analyzed and used to
arbitrarily divide samples into four intensity classes:
negative (less than 30 intensity), low (between 30 and 50
intensity), medium (between 51 and 70 intensity), and
high (greater than 70 intensity).
Total RNA isolation and quantitative real-time PCR
Total RNA was isolated using TRIzol reagent (Invitro-
gen) according to the manufacturer’si n s t r u c t i o n s .T h e
SuperScript III Reverse Transcription kit (Invitrogen)
was used to reverse transcribe 1 μgo ft o t a lR N Ai na
total volume of 25 μl. The real-time PCR reaction was
performed using the Stratagene Brilliant II SYBR green
QPCR Kit (La Jolla, CA) as suggested using 10 pmol of
forward and reverse primers for each PRLR isoform [24]
in a Stratagene Mx3005P starting with a 10 min incuba-
tion at 95°C followed by 40 cycles (95°C for 30 sec, 55°C
for 1 min, 72°C for 1 min). Data were analyzed using
the ΔΔCT method (Livak and Schmittgen 2001) with
GAPDH as the housekeeping control.
Results
Characterization of isoform specific antibodies
By RT-PCR, we had previously demonstrated that PRLR
was overexpressed in 80% of biopsy samples compared
to normal tissue [7]. However, until now, there were no
reliable antibodies available to examine the PRLR iso-
form profile by immunohistochemical techniques. To
characterize PRLR expression in human breast cancer
s a m p l e sr e q u i r e sr o b u s ta n t i b o d i e st h a ta r es p e c i f i ct o
each isoform. Thus we prepared and characterized poly-
clonal antibodies that specifically identify each of the
major cell associated isoforms, LF, SF1a and SF1b. CHO
cells were transiently transfected with cDNA containing
the individual PRLR isoforms; Figure. 1A shows the spe-
cificity of our antibodies by western blot. Cell lysate was
separated by SDS-PAGE and probed with the antibodies.
Each antibody correctly bound to its corresponding pro-
tein. No cross-reactivity was seen. The antibody pre-
pared against SF1a isoform was also able to bind the
PRLR isoform Δ7/11 as it shares sequence homology
with SF1a but lacks the transmembrane domain (exons
7-11, [7]). Using our polyclonal antibodies in immuno-
precipitation experiments enhanced the intensity of sig-
nal produced by western blot analysis, but did not
change the overall results (Figure 1A, far right).
In parallel, two commercially available antibodies were
also tested by western blot. A monoclonal antibody
(Invitrogen, 95-9200), raised against the extracellular
domain common to all PRLR isoforms, recognized all
three isoforms from transiently transfected CHO cells
(Figure 1B) as did the polyclonal antibody (Invitrogen,
34-9600) against SF1a (data not shown).
In addition, by immunocytochemical analysis, we were
able to stain CHO cells transiently transfected with
PRLR isoform specific cDNA (Figure 1C). Only cells
expressing the individual isoforms showed positive stain-
ing with its respective antibody. No cross-reactivity was
identified using the antibodies on cells transfected with
non-corresponding PRLR cDNA. Thus, each PRLR anti-
body was able to specifically detect its own isoform by
both western blot and immunocytochemical analyses.
Immunostaining of human breast cancer xenografts
Once we fully identified the specificity of the polyclonal
antibodies using transiently transfected CHO cells, we
tested their utility on xenografts obtained from human
breast cancer cell lines. MCF7, MDA-MB-231, or T47D
cells were injected into the cleared mammary fat pads of
nude mice to produce xenografts. As expected, based on
our previous studies examining the mRNA levels of the
PRLR isoforms by RT-PCR [7], the immunofluorescent
staining also showed considerable variation in PRLR
protein expression among the 3 groups of xenografts
examined (Figure 2A). LF antigen was expressed in all
the xenografts to varying degrees. SF1b was highly
stained in xenografts from all three cell lines. SF1a was
comparably less visible in MCF7 and MDB-MB-231
xenografts, but was also expressed at low levels in sec-
tions from T47D xenografts. Similar results were
observed using DAB as the chromogen (Figure 2B), a
detection method that is used most commonly in the
clinics, with one exception. LF expression was less visi-
ble in MCF7 and T47D xenografts with DAB when
compared to immunofluorescent staining. This differ-
ence may be due to how the antibody binds to either
horseradish peroxidase (forD A B )o rF I T C( f o rf l u o r e s -
cence) conjugated secondary antibody.
Differences in PRLR isoform expression was also con-
firmed by western blot analysis using xenograft lysates
prepared from tumors arising from MDA-MB-231 or
MCF7 cells (Figure 3). Relative levels of expression var-
ied between immunohistochemical and western analyses,
possibly due to differences in the expression of the
exposed epitopes. All three isoforms were detected in all
t h et u m o r s ,w i t hL Fa n dS F 1 am o r eh i g h l ye x p r e s s e d
than SF1b in MCF7 xenograft lysates. Expression of the
isoforms was less apparent, but still observed, in lysates
from MDA-MB-231 xenografts. These data suggested
that the isoforms of the PRLR are found in human
Ginsburg et al. BMC Cancer 2010, 10:678
http://www.biomedcentral.com/1471-2407/10/678
Page 4 of 11Figure 1 Characterization of PRLR isoform antibodies. A. Western blot analysis indicating specificity of polyclonal antibodies. CHO cells were
transiently transfected with isoform specific PRLR cDNA as described. Cell lysates were prepared and proteins separated by PAGE. Each isoform
specific lysate was probed with each isoform specific antibody. Each transfection was performed in triplicate and Western blot analysis
performed twice. Data shown are a representative autoradiogram. Molecular weights are marked as indicated: LF = 93 kDa, SF1a = 57 kDa,
SF1b = 38 kDa. Cell lysates from CHO transfected cells were immunoprecipitated with their respective antibodies, then immunoblotted with the
same antibodies. Each transfection was performed in triplicate and Western blot analysis performed twice. Data shown are a representative
autoradiogram. IP indicates immunoprecipitation. B. Western blot analysis using commercially available PRLR antibody. ECD = antibody
recognizing extracellular domain C. Fluorescent immunocytochemical analysis. CHO cells were transiently transfected with isoform specific PRLR
cDNA as described. Specific staining was observed using isoform specific polyclonal antibodies. The negative control (not shown) lacks primary
antibody and appears black. Data shown are representative of triplicate experiments. Magnification 20×.
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PRLR isoforms could be used to qualitatively distinguish
subtypes of breast cancer.
PRLR isoform gene expression by qPCR
To characterize PRLR isoforms in breast cancer we
performed qPCR (Figure 4) on 7 ductal and 7 lobular
carcinoma specimens selected at random from samples
that were also immunostained using our isoform
specific antibodies. Samples were obtained from the
CHTN as pathological waste with no clinical data.
Message levels for SF1a was very low for all samples
tested; as a result, message for LF or SF1b was com-
pared to SF1a. As depicted in Figure 4, mRNA levels
for LF were comparable between ductal and lobular
carcinoma biopsies. While it was difficult to specifically
quantify SF isoform expression by qPCR, in the lobular
carcinoma samples analyzed, SF1b expression was
nearly 2-fold higher than that in ductal carcinomas.
These data suggested that isoforms expression could
be used to distinguish breast cancer subtypes. Since we
Figure 2 Immunoanalysis on human xenografts. A. Fluorescent
immunohistochemistry was performed on MCF7, MDA-MB-231, or
T47D cells which were injected into the cleared fat pads of nude
mice; once tumors reached 1 cm
2 (measured in two dimensions),
they were excised, formalin fixed, sectioned, and stained with the
indicated PRLR isoform specific antibodies. B. Immunohistochemical
analysis using DAB as chromogen of MCF7, MDA-MB-231, or T47D
xenograft tumors. neg = no primary antibody as negative control;
DAPI stain to visualize the presence of cells. Photographs are
representative from 5 different tumors for each cell line.
Magnification 40×.
Figure 3 Western blot analysis using lysates prepared from
MDA MB 231 or MCF7 xenografts. Three separate tumors from
three separate animals for each cell type were separated by PAGE,
probed with either LF, SF1a, or SF1b specific antibody, and detected
by ECL.
Figure 4 Message for PRLR isoforms in breast carcinomas. RNA
was extracted from 7 ductal (left) and 7 lobular (right) carcinomas
and qPCR was performed. Data shown are the mean +/- SE of delta
delta Ct values relative to SF1a expression.
Ginsburg et al. BMC Cancer 2010, 10:678
http://www.biomedcentral.com/1471-2407/10/678
Page 6 of 11had previously demonstrated that genotype may not
always correlate with phenotype [25], we examined the
staining pattern in 12 ductal and 10 lobular carcino-
mas (data not shown). Similar to the staining pattern
identified in xenografts, we were able to observe wide
differences in the staining intensity across the exam-
ined samples. The amount of PRLR isoform expression
is as varied as the individual necessitating analysis of
larger numbers of samples.
PRLR isoform expression in human breast biopsy samples
In order to determine whether the PRLR isoform
expression pattern could aid in identification of breast
cancer subtype, we examined 144 ductal and 104 lobular
carcinoma biopsies available on tissue arrays with lim-
ited clinical information. Similar to what was observed
in the individual tumor section above, staining for both
the ductal and lobular carcinoma biopsies present on
the tissue arrays varied (Figures 5 and 6). The vast
majority of the samples, regardless of whether they were
of ductal or lobular origin, stained for PRLR LF (ductal
= 92%, lobular = 94%; see inserts Figures 5 and 6).
However, ductal carcinoma specimens showed a nearly
2-fold higher percentage of high LF staining when com-
pared to lobular carcinomas. In addition, differences
were observed when staining for PRLR short forms.
Staining with DAB as the chromogen also showed dif-
ferences in PRLR isoform expression (Figure 7). While
the distribution of expression levels of SF1b were similar
for ductal and lobular carcinomas, the majority (76%) of
ductal carcinoma biopsies expressed SF1a while the
majority of lobular carcinomas lacked SF1a staining
(72%) and 27% had only low levels of expression. These
data suggest that the relativee x p r e s s i o no fl e v e l so f
PRLR isoforms may aid in diagnosis of ductal vs. lobular
carcinomas. Obviously more samples, with attendant
clinical information, would need to be examined for sta-
tistical validation and to determine whether PRLR SF
expression could be routinely used to distinguish
between the breast cancer subtypes.
Discussion
Recent evidence indicates that high levels of PRL in
blood imparts increased risk of developing breast cancer,
Figure 5 Immunohistochemical analysis from ductal breast tissue arrays. Representative photographs taken of ductal carcinoma specimens
to demonstrate absent, low, medium, or high amounts of fluorescent red intensity staining. 144 individual ductal specimens were stained with
PRLR isoform specific antibodies and analyzed. Scale bar indicates range of red scoring.
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the case-controlled prospective Nurses’ Health Study
cohort of 851 patients found no difference in relative
risk for postmenopausal breast cancer in ductal vs lobu-
lar cancer with elevated PRL plasma levels [26], our
more recent data using a population-based case-con-
trolled study of 773 women from Poland has shown that
serum PRL levels were significantly higher in post-
menopausal women with invasive lobular compared to
ductal carcinoma [27].
The incidence of ductal carcinomas has remained
steady from 1987-1999 while the rate of lobular carcino-
mas has increased [28]. Perhaps this change is due to
better detection methods, even though lobular carci-
noma is generally more difficult to diagnose. Work done
by Zhao et al. [2,4,16] has shown that, at the molecular
level, lobular carcinomas have distinct gene expression
patterns compared to ductal carcinomas. Whether these
differences suffice to choose treatment options is open
for debate. It is becoming clear that the future of cancer
care will rely on personalized medicine. There are multi-
ple types or classifications of breast cancer and in order
to more rationally deliver the most effective treatment
we must know as much as possible about an individual
patient’s disease at the molecular level. This includes all
systems that impact on the cell fate of precancerous and
cancerous breast cells. Breast tumors are currently clas-
sified by the expression of ER and PR and whether they
overexpress Her2. These receptors are used because of
their known involvement in development and progres-
sion of breast cancer. Recent evidence has clearly indi-
cated that PRL plays a role in human breast cancer [2,4]
and hence the receptors for this important hormone
should also be assessed in all breast cancer cases.
PRL’s action is mediated by its receptors that exist in
multiple isoforms with common extracellular ligand
binding and transmembrane domains but different intra-
cellular domains resulting from alternate splicing [7].
Three major cell-associated isoforms are the LF, and
SF1a and SF1b. While the functions and signaling path-
ways utilized by the LF have been studied extensively
[4], similar studies of the short forms have been sparse.
While it has been known for some time that the short
forms of the PRLR can act as dominant negatives of the
Figure 6 Immunohistochemical analysis from lobular breast tissue arrays. Representative photographs of lobular carcinoma specimens to
demonstrate absent, low, medium, or high amounts of fluorescent red intensity staining. 104 individual lobular specimens were stained with
PRLR isoform specific antibodies and analyzed. Scale bar indicates range of red scoring.
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[7,11,29] or down regulation of expression of the LF
[8,30], their function in the native setting has not been
determined. In transfected cells, SF1a is a weak domi-
nant negative of the LF for differentiation [7]. However,
SF1a, as a homodimer, has the ability to activate the
casein promoter [11,31]. SF1b is a strong dominant
negative of the differentiative function of LF. In prostate
cancer, treatment with the PRL inhibitor S179D PRL
upregulated the expression of SF1b thus leading to
upregulation of p21, a cell cycle inhibiting protein, and
the vitamin D receptor known to promote differentia-
tion [32]. Long-term, increased expression of SF1b not
only decreased growth of prostate cancer cells in cul-
ture but also decreased cell migration and enhanced
cell-matrix interactions and cell-cell aggregation [33].
Recent evidence has shown that the PRLR was overex-
pressed in ductal vs acinar adenocarcinoma of the
prostate at both the transcript and the protein level
[34]. PRLR transcripts identified from microdissected
cell populations were elevated 6-fold in ductal vs.
acinar carcinoma cells. Validation by immunohisto-
chemical analysis, using an antibody that does not dis-
tinguish the isoforms, showed diffuse strong staining in
75% of ductal carcinoma regions in the 20 mixed
acinar-ductal adenocarcinoma cases compared to 20%
in acinar carcinoma regions. The majority of the acinar
carcinoma regions showed no staining or low levels of
patchy staining. That SF1b can inhibit the expression
levels of LF through accelerated degradation of the LF
message [30] suggests that the LF:SF1b ratio may be
relevant to tumor growth.
PRLR transcripts have been described in up to 90% of
breast cancers suggesting that their presence or absence
may not be as important as the distribution of the iso-
forms. It is clear that mRNA for all three forms are present
in many breast cancers [7,12]; the distribution of the iso-
form protein has not been ascertained. To properly assess
this, isoform specific antibodies needed to be developed
[35]. The polyclonal antibodies described in this paper pro-
vide the first clearly isoform specific tools that can be used
to determine where and how the isoforms interact.
Conclusions
We have successfully developed PRLR isoform specific
antibodies that can be used to detect proteins by wes-
tern blot, immunoprecipitation, and immunocyto/histo-
chemical analyses. These antibodies may help us
correlate receptor isoforms in both breast development
and in cancer. We found differences in expression levels
Figure 7 Immunohistochemical analysis of a representative ductal carcinoma using DAB as a chromogen. neg = no primary antibody as
negative control; DAPI stain to visualize the presence of cells. Magnification 40×.
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Page 9 of 11for the PRLR isoforms in lobular vs. ductal carcinomas
that demonstrate these antibodies may be used as a new
clinical tool to distinguish between subclasses of breast
cancer. These insights may prove important in the treat-
ment of breast cancer and other PRL responsive
diseases.
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